UBS Group
PTCT icon

UBS Group’s PTC Therapeutics PTCT Stock Holding History

UBS Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,800
Closed -$2.06M – 9369
2020
Q4 		$2.06M Buy
+33,800
New +$1.99M ﹤0.01% 3384
2017
Q2 		– Sell
-159,200
Closed -$1.57M – 7912
2017
Q1 		$1.57M Buy
+159,200
New +$1.93M ﹤0.01% 3155
2015
Q2 		– Sell
-5,000
Closed -$304K – 8758
2015
Q1 		$304K Buy
+5,000
New +$305K ﹤0.01% 4542

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

UBS Group's PTCT Position: Q2 2026 in Review

UBS Group reduced its PTC Therapeutics (PTCT) stake by 81% in Q2 2026, selling an estimated $79.6M and leaving 262,426 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2612.

UBS Group first reported a position in PTCT in Q4 2014 and has held it in 47 quarters since. The position peaked at $93M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • UBS Group held 262,426 shares of PTC Therapeutics worth $21.4M as of Q2 2026.
  • UBS Group sold 1,102,342 PTC Therapeutics shares in Q2 2026, an estimated $79.6M.
  • PTC Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2612 holding.
  • UBS Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's PTC Therapeutics position peaked at $93M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.